HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.

Abstract
Tetrahydro-N, N-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) binds to muscarinic acetylcholine and sigma(1) (σ(1)) receptors with affinities in the low micromolar range. We characterized its anti-amnesic and neuroprotective potentials in pharmacological and pathological amnesia models. Spatial working memory was evaluated using spontaneous alternation in the Y-maze and non-spatial memory using passive avoidance procedures. ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments. ANAVEX2-73 (300 µg/kg) also reversed the learning deficits in mice injected with Aβ(25-35) peptide, a non-transgenic Alzheimer's disease model. When the drug was injected simultaneously with Aβ(25-35), 7 days before the tests, it blocked the appearance of learning impairments. This protective activity was confirmed since ANAVEX2-73 blocked the Aβ(25-35)-induced oxidative stress in the hippocampus. This effect was differentially sensitive to the muscarinic receptor antagonist scopolamine or the σ(1) protein antagonist BD1047, confirming the mixed muscarinic/σ(1) pharmacological action. Finally, its unique demethyl metabolite, ANAVEX19-144, was also effective and ANAVEX2-73 presented a longer duration of action, effective 12 h before Aβ(25-35), than its related compound ANAVEX1-41. The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ(1) activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.
AuthorsVanessa Villard, Julie Espallergues, Emeline Keller, Alexandre Vamvakides, Tangui Maurice
JournalJournal of psychopharmacology (Oxford, England) (J Psychopharmacol) Vol. 25 Issue 8 Pg. 1101-17 (Aug 2011) ISSN: 1461-7285 [Electronic] United States
PMID20829307 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amyloid beta-Peptides
  • Delayed-Action Preparations
  • Furans
  • Ligands
  • Neuroprotective Agents
  • Peptide Fragments
  • Receptors, Muscarinic
  • Receptors, sigma
  • amyloid beta-protein (25-35)
  • tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride
  • tetrahydro-N, N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride
Topics
  • Alzheimer Disease (drug therapy, physiopathology)
  • Amyloid beta-Peptides (toxicity)
  • Animals
  • Avoidance Learning
  • Delayed-Action Preparations (administration & dosage, metabolism, pharmacology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Furans (metabolism, pharmacology)
  • Hippocampus (drug effects, pathology)
  • Ligands
  • Male
  • Memory, Short-Term (drug effects)
  • Mice
  • Neuroprotective Agents (administration & dosage, metabolism, pharmacology)
  • Oxidative Stress (drug effects)
  • Peptide Fragments (toxicity)
  • Protein Binding
  • Receptors, Muscarinic (metabolism)
  • Receptors, sigma (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: